# OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

> **NCT06068049** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 500 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06068049
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-28
- **Primary completion:** 2029-06-15
- **Final completion:** 2029-06-15
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068049, "OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06068049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*